Specific induction of CD33 expression by E2A–HLF: the first evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factor

Article metrics

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2
Figure 3

References

  1. 1

    Wiersma SR, Ortega J, Sobel E, Weinberg KI . Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 1991; 324: 800–808.

  2. 2

    Pui CH, Behm FG, Singh B, Rivera GK, Schell MJ, Roberts WM et al. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 1990; 75: 198–202.

  3. 3

    Mejstrikova E, Kalina T, Trka J, Stary J, Hrusak O . Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy. Leukemia 2005; 19: 1092–1094.

  4. 4

    Paul SP, Taylor LS, Stansbury EK, McVicar DW . Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 2000; 96: 483–490.

  5. 5

    Inukai T, Hirose K, Inaba T, Kurosawa H, Hama A, Inada H et al. Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. Leukemia 2007; 21: 288–296.

  6. 6

    Inaba T, Roberts WM, Shapiro LH, Jolly KW, Raimondi SC, Smith SD et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 1992; 257: 531–534.

  7. 7

    Bodger MP, Hart DN . Molecular cloning and functional analysis of the CD33 promotor. Br J Haematol 1998; 102: 986–995.

  8. 8

    van der Velden AHJ, te Marvelde JG, Hoogeveen PG . Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197–3204.

Download references

Acknowledgements

We thank K Nakamura (Hiroshima University, Hiroshima, Japan), Y Nagatoshi (National Kyushu Cancer Center, Fukuoka, Japan), Y Ohtsuka (University of Tokyo, Tokyo, Japan), H Inada (Kurume University School of Medicine, Kurume, Japan), and K Nakamura (Teikyo University, Tokyo, Japan) for providing clinical data of cell surface antigen expression, Wyeth Research (Pearl River, NY, USA) for providing GO, F. Rauscher III (Wister Institute, PA, USA) for providing pMT-CB6+ expression vector, and Y Akahane (Scientific Coordination Group Inc., Saitama, Japan) for sterile splitting of GO.

Author information

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Akahane, K., Inukai, T., Inaba, T. et al. Specific induction of CD33 expression by E2A–HLF: the first evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factor. Leukemia 24, 865–869 (2010) doi:10.1038/leu.2010.8

Download citation

Further reading